Fig 1.
Timeline of the prospective study, *120 mg twice daily, **240 mg twice daily, Rx-refills.
Table 1.
PwMS demographic and clinical characteristics.
Fig 2.
Scatterplot of the weighted CMA 7 measure and the MARS-5 at the follow-up brain MRI, number of PwMS N = 40.
Table 2.
Comparison of the MARS-5 score and the weighted CMA7 adherence measure.
Table 3.
Validity of the MARS-5 questionnaire.